Industry snapshot
Key public data points
Historical & forecast
Base year 2025. Each series is official through its own latest government-data year (shown in the legend on each chart), and years beyond that are Claight estimates. As of July 2026 the current year is still in progress (2026 annual data is not yet published), so the forecast runs to 2030.
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Industry Definition and Scope
What does the Biotechnology in Australia industry cover?
The Australian biotechnology industry involves the application of cellular, molecular, and genetic technologies across human health, agriculture, and industrial biomanufacturing. Activity spans early-stage discoveries in university laboratories to clinical-stage therapeutic development and commercial-scale manufacturing. Primary sub-sectors include biopharmaceuticals, diagnostics, agricultural biotechnology, and synthetic biology.
- •Human health applications represent over half of all operating entities, covering biotherapeutics, vaccines, and cell and gene therapies.
- •Agricultural and industrial applications include genetically modified crops, biological pest controls, and biofuel research.
- •The sector relies on research translation from major public research institutions such as CSIRO and Australian universities.
Market Structure and Operators
Who operates in the industry and how is it structured?
Australia's biotechnology sector consists of a large tier of early-stage spin-outs and research organisations alongside a smaller tier of commercialised public firms. Geographical concentration is highest along the eastern seaboard near established university and hospital research precincts. Growth is sustained through public capital markets, government research grants, and international co-investment.
- •New South Wales and Victoria collectively host over 70 percent of all life sciences organisations in Australia as of 2022.
- •Industry-based commercial enterprises account for 54 percent of all registered biotechnology organisations.
- •Contract research organisations (CROs) and phase-I clinical trial centres form a critical fee-for-service support layer.
Demand Drivers
What drives demand in the industry?
Demand for biotechnology solutions is driven by chronic health burdens, an ageing demographic, and national targets for food security and biosecurity. Government funding mechanisms and tax incentives directly stimulate research activity and international clinical trial placement in Australia. Furthermore, global biopharma demand for high-quality early-stage clinical trial data underpins service exports.
- •The Research and Development Tax Incentive (R&DTI) provides tax offsets to eligible entities undertaking R&D activities in Australia.
- •The Australian Government's Medical Research Future Fund (MRFF) provides long-term grant allocations for medical research translation.
- •Favourable regulatory acceptance of Australian clinical trial data by the US FDA and European Medicines Agency accelerates international trial demand.
Competitive Landscape and Notable Public Companies
Who are the notable companies in the industry?
The commercial landscape is characterized by intense competition for intellectual property, capital, and skilled talent. While small-to-medium enterprises predominate in numbers, large-cap firms dominate sector revenue and commercial manufacturing capacity. Key domestic and international participants drive pipeline development across diverse therapeutic categories.
- •CSL Limited is Australia's largest biopharmaceuticals company, specializing in plasma therapies, influenza vaccines, and cell therapies.
- •Telix Pharmaceuticals Limited operates in radiopharmaceutical technology for cancer imaging and targeted therapy.
- •Mesoblast Limited develops allogeneic cellular medicines for inflammatory and degenerative conditions.
- •Neuren Pharmaceuticals Limited focuses on therapies for neurodevelopmental disorders.
Recent Trends and Outlook
What are the recent trends and outlook?
Key trends in the industry include expanding domestic biomanufacturing infrastructure, accelerated growth in cell and gene therapies, and synthetic biology commercialisation. Government co-investment programs aim to bridge the translation gap between clinical discovery and sovereign commercial manufacturing. Long-term projections indicate expanding economic output across biosecurity, agriculture, and precision medicine.
- •The National Reconstruction Fund (NRF) has earmarked 1.5 billion AUD in co-investment capital specifically for medical manufacturing.
- •CSIRO projects the Australian synthetic biology national market potential to reach 27 billion AUD in annual revenue by 2040.
- •Domestic investment in mRNA biomanufacturing facilities in Victoria and Queensland has expanded national bio-preparedness.
Regulation and Compliance
How is the industry regulated?
Biotechnology operations in Australia are heavily regulated to ensure safety, efficacy, and environmental containment. Human health therapeutics and diagnostic devices are evaluated by national medical authorities prior to market supply. Gene technology and genetically modified organisms are managed under strict statutory oversight.
- •The Therapeutic Goods Administration (TGA) regulates pharmaceuticals, biologicals, and medical devices under the Therapeutic Goods Act 1989.
- •The Office of the Gene Technology Regulator (OGTR) administers the Gene Technology Act 2000 to protect human health and the environment from GMO risks.
- •The Clinical Trials Notification (CTN) and Clinical Trials Approval (CTA) schemes govern human research compliance across clinical sites.
Sources
Government, statistical and trade sources used for this Claight analysis.
- AusBiotech Australian Biotechnology Sector Snapshot 2022 ·
- Australian Trade and Investment Commission (Austrade) 2023 ·
- Department of Health and Aged Care Medical Research Future Fund 2022 ·
- Commonwealth Scientific and Industrial Research Organisation (CSIRO) 2021 ·
- Australian Bureau of Statistics ANZSIC 2006
Claight analysis of public industry data.